Over the weekend, Clovis Oncology took another big step toward its near-term goal of launching commercial operations, with plans to take pharma giant AstraZeneca head-on with two key franchise showdowns. The Boulder, CO-based biotech posted positive data from a mid-stage study of its ovarian cancer drug rucaparib at ASCO, while adding new–though less impressive–data to back up its lead drug for non-small cell lung cancer.

…read more

Source: UPDATED: Clovis boasts promising ovarian cancer data as lung cancer results fade